1. 500 Pembrolizumab (MK-3475) for PD-L1-positive squamous cell carcinoma (SCC) of the anal canal: Preliminary safety and efficacy results from KEYNOTE-028. Issue 3 (September 2015) Authors: Ott, P.A.; Piha-Paul, S.A.; Munster, P.; Pishvaian, M.J.; Van Brummelen, E.; Cohen, R.; Gomez-Roca, C.; Ejadi, S.; Stein, M.; Chan, E.; Simonelli, M.; Morosky, A.; Yuan, S.S.; Koshiji, M.; Bennouna, J. Journal: European journal of cancer Issue: Volume 51:Issue 3(2015:Feb.) Page Start: S102 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗